Huntington Disease Pathology Unfolds

Courtesy: Larry Marsh and Judit Pallos  IN A FLY'S EYE: The regular repeating structure of the Drosophila melanogaster compound eye is disrupted when polyglutamine (polyQ 108) is expressed, making the fly eye an excellent model for huntingtin-derived pathology. Dissecting the mechanism of neuronal demise in Huntington disease (HD) has had its share of twists and turns. It took a decade to go from marker1 to gene,2 and now, after another decade, the details are beginning to come together.

Written byRicki Lewis
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Dissecting the mechanism of neuronal demise in Huntington disease (HD) has had its share of twists and turns. It took a decade to go from marker1 to gene,2 and now, after another decade, the details are beginning to come together. Three papers published in 2001 focus on two key roles for the pathological form of huntingtin protein--interfering with transcription3,4 and plugging up proteasomes, the cellular trash compactors for misfolded proteins.5 While different, these hypotheses are not mutually exclusive, and may point to multiple effects that inevitably cause the devastating symptoms of HD.

In the late 1800s, Long Island physician George Huntington lent his name to this disorder, which is characterized by uncontrollable, dancelike movements and personality changes.6 After a long illness, individuals with HD die from complications such as choking or infection. The genetic marker discovered in 1983 had the uninspiring name G8 and the gene discovered 10 years later ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies